Researchers are constantly seeking ways to improve existing drugs, drug 
mechanisms of activity, find new indications for old drugs or to develop new 
drugs to treat urological diseases and conditions. In Canada, tadalafil in a 5 
mg daily dosage (old drug), and a new drug, silodosin, have recently become 
available to treat patients who have benign prostatic hyperplasia (BPH) with 
lower urinary tract symptoms (LUTS). In clinical studies, silodosin has shown 
promise as a treatment for ureteral stones, whereas it has shown conflicting 
results as a potential treatment for prostatitis. Two new therapies have emerged 
for treating overactive bladder (OAB): Mirabegron (not yet available in Canada) 
and fesoterodine (newly introduced in the marketplace). New therapies--denosumab 
(to prevent skeletal events) and abiraterone acetate and enzalutamide--were 
recently approved to treat certain patients with advanced prostate cancer. With 
the advent of new therapies to treat urological diseases, in many cases, primary 
management of the patient is often shifted from the urologist to the family 
physician, and sometimes moved from the oncologist to the urologist.